Spoken Alpha
Vericel Corp
Vericel Corporation provides cell therapy and specialty biologic products for sports medicine and severe burn care. The company markets MACI, an autologous cartilage repair product for knee defects; Epicel, a cultured skin replacement for large burns; and NexoBrid, an enzyme treatment for burn wound debridement.
Vericel Corp is a Healthcare company operating in Biotechnology with a $2.02B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VCEL.
$ curl https://api.spokenalpha.com/v1/companies/VCELFAQ
Spoken Alpha indexes VCEL's earnings call transcripts at https://spokenalpha.com/companies/VCEL. Each call links to attributed speakers and parsed analyst Q&A. Vericel Corp's own investor relations page is at https://investors.vcel.com/press-releases.
Vericel Corp (VCEL) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
Vericel Corp (VCEL) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $0.02 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $0.04 | $-0.04 | +100.0% | $77.5M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.12 | $-0.16 | +25.0% | $68.4M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.45 | $0.45 | 0.0% | $92.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.10 | $-0.01 | +100.0% | $67.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $-0.01 | $-0.04 | +75.0% | $63.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.23 | $-0.15 | -53.3% | $52.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $0.38 | $0.34 | +11.8% | $75.4M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.02 | $-0.05 | +60.0% | $57.9M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.10 | $-0.09 | -11.1% | $52.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.08 | $-0.10 | +20.0% | $51.3M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $0.26 | $0.17 | +52.9% | $65.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.05 | $-0.12 | +58.3% | $45.6M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-0.11 | $-0.15 | +26.7% | $45.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.16 | $-0.16 | 0.0% | $41.0M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $0.12 | $0.04 | +100.0% | $52.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.14 | $-0.10 | -40.0% | $38.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $-0.19 | $-0.12 | -58.3% | $37.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.15 | $-0.12 | -25.0% | $36.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $0.09 | $0.14 | -35.7% | $47.6M | — | — | EODHD |
Source: EODHD. VCEL reported actuals as published; sparse fields render as —.